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Sickle cell disease promotes hemolytic anemia and occlusion of small blood vessels due to the presence 
of high concentrations of hemoglobin S, resulting in increased production of reactive oxygen species 
and decreased antioxidant defense capacity. The aim of this study was to evaluate the protective action 
of a standardized extract of Ginkgo biloba (EGb 761), selected due to its high content of flavonoids 
and terpenoids, in erythrocytes of patients with sickle cell anemia (HbSS, SS erythrocytes) subjected 
to oxidative stress using tert-butylhydroperoxide or 2,2-azobis-(amidinepropane)-dihydrochloride, in 
vitro. Hemolysis indexes, reduced glutathione, methemoglobin concentrations, lipid peroxidation, and 
intracellular reactive oxygen species were determined. SS erythrocytes displayed increased rates of 
oxidation of hemoglobin and membrane lipid peroxidation compared to normal erythrocytes (HbAA, AA 
erythrocytes), and the concentration of EGb 761 necessary to achieve the same antioxidant effect in SS 
erythrocytes was at least two times higher than in normal ones, inhibiting the formation of intracellular 
reactive oxygen species (IC50 of 13.6 µg/mL), partially preventing lipid peroxidation (IC50 of 242.5 µg/mL)  
and preventing hemolysis (IC50 of 10.5 µg/mL). Thus, EGb 761 has a beneficial effect on the oxidative 
status of SS erythrocytes. Moreover, EGb 761 failed to prevent oxidation of hemoglobin and reduced 
glutathione at the concentrations examined.
Uniterms: Ginkgo biloba. Oxidative stress. Erythrocytes. Azo compounds. Sickle cell anemia.
A doença falciforme promove anemia hemolítica e oclusão dos pequenos vasos, causados pela presença 
de altas concentrações de hemoglobina S, cujas consequências incluem a produção aumentada de espécies 
reativas de oxigênio e diminuição da capacidade de defesa antioxidante. O objetivo desse estudo foi 
avaliar a ação protetora de um extrato padronizado de Ginkgo biloba (EGb 761), selecionado devido 
ao seu alto conteúdo de flavonóides e terpenóides, em eritrócitos de pacientes com anemia falciforme 
(HbSS, eritrócitos SS) submetidos ao estresse oxidativo usando terc-butil-hidroperóxido e 2,2-azobis-
(amidinopropano)-diidrocloreto, in vitro. Índices de hemólise, glutationa reduzida, concentração de 
metemoglobina, peroxidação lipídica e espécies reativas de oxigênio foram determinados. Eritrócitos 
de pacientes com anemia falciforme apresentaram taxas aumentadas de oxidação da hemoglobina e 
peroxidação lipídica e a concentração de EGb 761 necessária para atingir o mesmo efeito antioxidante 
foi pelo menos duas vezes maior em relação aos eritrócitos normais (HbAA, eritrócitos AA), inibindo a 
formação de espécies reativas de oxigênio (IC50 de 13.6 µg/mL), prevenindo parcialmente a peroxidação 
lipídica (IC50 de 242.5 µg/mL) e prevenindo a hemólise (IC50 de 10.5 µg/mL). Portanto, EGb 761 possui 
um efeito benéfico no estado oxidativo dos eritrócitos SS. Entretanto, o EGb 761 não preveniu a oxidação 
da hemoglobina e da glutationa reduzida, nas concentrações examinadas.
Unitermos: Ginkgo biloba. Estresse oxidativo. Eritrócitos. Compostos azo. Anemia falciforme.
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INTRODUCTION
In hemoglobinopathies, including sickle cell disease 
(SCD), red blood cells are rendered more susceptible to 
oxidative damage because they produce greater amounts of 
reactive oxygen species (Aslan, Thornley-Brown, Freeman, 
2000). Moreover, in SCD red blood cells are more suscep-
tible to oxidation (Chaves, Leonart, Nascimento, 2008) and 
have a reduced ability to defend against oxidation (Fasola et 
al., 2007). The imbalance between pro- and antioxidant ac-
tions can lead to extensive oxidative damage of erythrocyte 
membrane components (Titus et al., 2004). SCD was the 
first monogenic human disease characterized at the molecu-
lar level. Erythrocyte defects observed in SCD resulted from 
the substitution of glutamic acid by valine at position 6 on 
the β chain of hemoglobin thus forming hemoglobin S (Hb 
S) rather than normal hemoglobin A (Hb A) (Higgs, Wood, 
2008). The SS genotype results in sickle cell anemia (SCA). 
Under conditions of low oxygen tension, Hb S molecules 
polymerize, causing erythrocyte deformation and increased 
membrane rigidity. As a consequence, anemia and chronic 
hemolytic occlusion of small blood vessels occur, leading 
to tissue damage by ischemia (Titus et al., 2004).
Recognition of the role of reactive oxygen species 
(ROS) in the pathophysiology of SCA suggests a beneficial 
effect of supplements that increase the total antioxidant 
capacity in patients, and thus, reduce oxidative damage 
in erythrocytes.
Extracts of Ginkgo biloba are widely consumed as 
herbal remedies and dietary supplements and its leaves have 
been used in Chinese medicine for thousands of years. In 
recent years, standardized Ginkgo biloba leaf extracts with 
well-defined components have been developed, including 
EGb 761, which contains 24% ginkgo-flavone glycosides 
and 6% terpenoids. Several studies have demonstrated the 
antioxidant action of EGb 761 in erythrocyte models of oxi-
dative stress (He et al, 2008; Kose et al, 1997; Sarikcioglu, 
Oner, Tercan, 2004; Foroughinia, Karimi, 2007). However, 
to our knowledge, this is the first study examining the effect 
of EGb 761 in the prevention of oxidative damage in SCD.
Thus, it was important to analyze the antioxidant ef-
fect of EGb 761 in the erythrocytes of SCA patients in order 
to investigate whether this extract can protect them from 
oxidative injury in vitro, and to provide support for the use 
of EGb 761 as an antioxidant supplement in vivo, enabling 
further evaluation of it as a possible therapy for this patients.
MATERIAL AND METHODS
Te r t - b u t y l h y d r o p e r o x i d e  ( t - B H P )  a n d 
2,2-azobis(amidinepropane) dihydrochloride (AAPH) 
were purchased from Across Organics and Sigma-Aldrich, 
respectively. EGb 761 was kindly donated from the Her-
barium, and dissolved in 50% propylene glycol in a stock 
solution of 20 mg/mL phosphate-buffered saline (PBS). 
All others reagents were of analytical grade.
Fresh blood was drawn from the antecubital vein 
of 20 healthy volunteers, students and professionals of 
Federal University of Paraná, considered as HbAA (AA 
erythrocytes) after normal blood count and hemoglobin 
solubility test; and 21 sickle cell disease patients, with 
previous diagnosis of HbSS (SS erythrocytes) condition 
by hemoglobin electrophoresis and solubility test, treated 
at Center of Hematology and Hemotherapy of Paraná 
(HEMEPAR) from October 2010 to February 2011, us-
ing EDTA K3 as an anticoagulant. Serum and buffy coats 
were removed by centrifugation at 1000 × g for 10 min, 
and the red blood cell pellets were washed three times in 
cold isotonic PBS (10 mmol/L, pH 7.4). All erythrocytes 
suspensions were freshly prepared on a daily basis. The 
survey was approved by the Ethics Committee of the Fed-
eral University of Paraná (CEP/SD 778.113.09.08), and 
all subjects signed an informed consent form.
For each analysis (methemoglobin, TBARS, GSH, 
hemolysis and ROS production) it were used 5 patient/con-
trol samples, in triplicate. The analyses were done in basal 
states, after oxidant incubation (AAPH/t-BHP) and after 
EGb 761 + oxidant incubation (EGb 761 pre-incubation 
of 30 min, according to He et al., 2008).
A stock solution of aqueous AAPH (100 mmol/L) 
was used in the hemolysis experiments. Suspensions of 
red blood cells (10% hematocrit) were incubated with EGb 
761 (0–250 μg/mL) at 37 oC for 30 min, followed by AAPH 
at 37 oC for 3 h under homogenization. Incubation was 
terminated by centrifugation at 1000 × g for 10 min, and 
the absorbance of the supernatants was measured at 540 
nm using a microplate reader (Thermoplate, Tecnoglobo, 
Brazil). The hemolysis of red blood cells in water was used 
as a control and was presumed to be 100%.
The level of reduced glutathione level (GSH) in red 
blood cells (40% hematocrit) was determined in basal 
state and after treatment with EGb 761 (0-250 μg/mL) and 
t-BHP (10 mmol/L), using 5,5’-dithio-bis(2-nitrobenzoic) 
acid (DTNB) as a chromophore, as previously described by 
Beutler, 1984. Absorbance was measured at 412 nm using 
a spectrophotometer (Cintra 10 UV-VIS, GBC, Australia).
The concentration of methemoglobin present in 
erythrocytes in basal state and after treatment with EGb 
761 (0-250 μg/mL) and t-BHP (1 mmol/L) was determined 
according to Naoum et al.(2004). Briefly, after treatment, 
an aliquot of the cell suspension (10% hematocrit) was 
hemolysed with 1% saponine prior to the addition of 
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phosphate buffer 60 mmol/L, pH 6.8. Absorbance of the 
solution was adjusted with PBS and then read at 540 nm 
and 630 nm spectrophotometrically.
Erythrocyte lipid peroxides were measured as thio-
barbituric acid reactive substances (TBARS) according to 
the protocol developed by Stocks and Dormandi, 1971, in 
basal state and after treatment. Erythrocytes (10% hema-
tocrit) were pre-incubated with EGb 761 (0-250 μg/mL) 
for 30 min at 37 oC and t-BHP (2 mmol/L) for 15 min at 
37 oC. Absorbance was determined spectrometrically and 
malonyldialdehyde concentrations were calculated.
Erythrocytes suspensions (10% hematocrit) were 
incubated in PBS at 37 ºC for 30 min in the presence of di-
chlorodihydrofluorescein-diacetate (DCF-DA) 10 µmol/L. 
After incubation with the probe, the cell suspension was 
diluted 1:10 in PBS 10 mmol/L, pH 7.4 and incubated with 
increasing concentrations of EGb 761 (0-250 μg/mL) for 30 
min at 37 oC. ROS production was determined by exposure 
to t-BHP (75 µmol/L for 15 min) at 37 oC using a fluorimeter 
(Synergy HT, Biotek, USA), as described by López and Re-
vuelta, 2005. Percentage of ROS formation was determined 
as DFC fluorescence/mg Hb, and experimental samples 
were normalized to the fluorescence emitted by erythrocytes 
loaded with DCF-DA in the presence of the t-BHP.
Values were presented as means ± standard devia-
tion. Statistical significance of the experimental data was 
analyzed using t test, ANOVA and Dunnet tests. A p<0.05 
value was considered to be significant. The Inhibitory Con-
centration (IC50) necessary to inhibit 50% of the oxidation 
by t-BHP was defined in Prism 5 for Windows (GraphPad 
Software, Inc) using a sigmoidal dose-response model 
with variable slope, considering group t-BHP (without 
EGb 761) as 0% of inhibition. The best fit values for IC50 
and its standard error were reported.
RESULTS
Basal levels of methemoglobin, TBARS and GSH 
SS erythrocytes presented an increased endogenous 
oxidative stress in relation to AA erythrocytes, as seen in 
methemoglobin and TBARS basal content, while the basal 
content of GSH was the same in both groups (Table I).
Pro-oxidant action of t-BHP on glutathione, 
methemoglobin and TBARS levels
Incubation of both AA and SS erythrocytes with the 
oxidant t-BHP led to the depletion of reduced GSH, forma-
tion of methemoglobin, and membrane lipoperoxidation. 
However, hemoglobin oxidation and lipid peroxidation 
were 1.2 and 1.9 times higher, respectively, in the SS group 
compared to the AA group (Table I).
Antioxidant action of EGb 761 on glutathione, 
methemoglobin and TBARS levels
In both AA and SS erythrocytes, the extract failed 
to prevent or reverse GSH and hemoglobin oxidation at 
the concentrations tested (Table I). Moreover, it partially 
prevented the peroxidation of membranes, both in eryth-
rocytes of healthy subjects and patients with SCA, in a 
dose-dependent manner. In erythrocytes from SCA pa-
tients, pre-incubation with concentrations of 250 µg/mL 
EGb 761 inhibited lipid peroxidation by 50.6% (Table I).
TABLE I - Erythrocytes concentration of TBARS, glutathione and methemoglobin levels in normal subjects (AA) and sickle cell 
anemia patients (SS) incubated with Ginkgo biloba extract (EGb 761) in the presence of tert-butyl hydroperoxide (t-BHP)*
Treatment
Glutathione§ Methemoglobin§§ TBARS§§§
(µmol/g Hb) (%) (nmol/g Hb)
AA SS AA SS AA SS
Basal 7.0 ± 0.9 7.2 ± 0.8 3.2 ± 0.3 5.0 ± 0.4a 21.2 ± 6.7 38.2 ± 5.9a
t-BHP 0.7 ± 0.3 0.4 ± 0.4 10.0 ± 1.6 12.0 ± 2.1 235.1 ± 37.1 445.2 ± 38.4
 EGb 761 (5µg/mL) + t-BHP 0.8 ± 0.5 0.4 ± 0.4 10.4 ± 2.2 11.9 ± 2.5 219.2 ± 39.6 466.9 ± 40.6
EGb 761 (10 µg/mL) + t-BHP 1.0 ± 0.7 - 9.4 ± 2.1 12.0 ± 2.1 212.9 ± 36.8 451.5 ± 34.4
EGb 761 (125 µg/mL)+ t-BHP 1.2 ± 0.8 - 10.2 ± 2.3 13.1 ± 2.3 201.9 ± 32.3 438.4 ± 54.9
EGb 761 (50 µg/mL)+ t-BHP 0.6 ± 0.3 0.4 ± 0.3 10.2 ± 2.4 12.6 ± 1.6 179.5 ± 32.7c 427.8 ± 76.5
EGb 761 (125 µg/mL)+ t-BHP 0.7 ± 0.7 - 9.8 ± 2.1 11.8 ± 2.2 123.3 ± 34.2b 314.9 ± 60.8b
EGb 761 (250 µg/mL)+ t-BHP 0.9 ± 0.8 0.3 ± 0.3 10.2 ± 2.6 13.1 ± 2.6 82.9 ± 26.7b 224.1 ± 40.1b
*Data represent the mean ± standard deviation of 5 analyses in triplicate. Methemoglobin is expressed as a percentage of total 
hemoglobin. [-] Not determined. t-BHP concentration: §10, §§1, §§§2 mmol/L. [Unpaired t test, P values: a<0.001 group SS Vs Group 
AA; ANOVA, P values: b<0.001, c<0.05 Vs Group t-BHP].
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Pro-oxidant action of AAPH on hemolysis
The degree of hemolysis in response to AAPH treat-
ment was determined to be reduced in erythrocytes from 
sickle cell patients compared to the control group. In the 
SS group, the hemolysis was 20%, while in the AA group 
it was 40% (Figure 1).
Antioxidant action of EGb 761 on hemolysis
EGb 761 showed significant anti-hemolytic action, 
preventing hemolysis at low concentrations (5 µg/mL) in 
both AA and SS erythrocytes. This protection was dose 
dependent, reaching maximum inhibition at 25 µg/mL 
(Figure 1).
Inhibitory Concentration 50% (IC50) of EGb 761
In in vitro assays, the concentration of EGB 761 ex-
tract required to inhibit 50% of lipid peroxidation induced 
by the oxidant (IC50) was 141.0 µg/mL in erythrocytes of 
the AA group and 242.5 µg/mL in erythrocytes from the 
SS group (Table II).
The IC50 of the extract in the control group to prevent 
hemolysis was approximately two times lower (4.5 µg/mL) 
than the levels observed in erythrocytes from sickle cell 
patients (10.5 µg/mL) (Table II).
Antioxidant action of EGb 761 on ROS production
We found that all of the concentrations of EGb 761 
tested inhibited ROS production when normal erythro-
cytes were exposed to t-BHP, and the level of protection 
reached 95.6% after incubation with EGb 761 125 µg/mL. 
In the erythrocytes of sickle cell patients, concentra-
tions ≥ 10 µg/mL significantly inhibited ROS formation 
and the maximum inhibition reached was 93.2% (Fig-
ure 2). Furthermore, EGb 761 showed greater activity in 
normal erythrocytes (IC50 of 4.48 µg/mL) compared to SS 
erythrocytes (IC50 of 13.6 µg/mL), which required more 
than twice the dose to achieve the same effect observed in 
the control group (Table II).
DISCUSSION
Patients with SCD exhibit continuous depletion of 
antioxidant nutrients and depressed antioxidant enzyme 
activity in response to chronic oxidative stress. Impairment 
of the antioxidant system is associated with the increased 
severity of clinical manifestations. Therefore, antioxidant 
supplementation has been shown to improve erythrocyte 
survival and clinical outcome (Chan, Xia, Fu, 2007). It is 
widely accepted that these patients have increased con-
centrations of reactive oxygen species (Aslan, Thornley-
Brown, Freeman, 2000; Morris et al., 2008). As expected, 
our experiments detected greater hemoglobin oxidation 
and lipid peroxidation in the erythrocytes of SS patients.
FIGURE 1 - Prevention of hemolysis in normal (■) and sickle 
cell anemia (●) erythrocytes by EGb 761 exposed to AAPH 
40 mmole/L. Each experimental point represents the mean ± 
standard deviation of 5 analyses in triplicate. [ANOVA, P values: 
a<0.001, b<0.05 Vs Group 0]. FIGURE 2 - Effect of EGb 761 on the inhibition of ROS 
production in normal (■) and sickle cell anemia (●) erythrocytes 
exposed to t-BHP 75 µmole/L. Each experimental point 
represents the mean ± standard deviation of 5 analyses in 
quadruplicate. [ANOVA, P value: *<0.001 Vs Group 0].
TABLE II - Inhibitory Concentration 50% (IC50) of EGb 761 
in isolated normal (AA) and sickle cell anemia (SS) human 
erythrocytes*
Group TBARS ROS Hemolysis
AA 141.0±1.1 4.8±1.1 4.5±1.3
SS 242.5±1.1 13.6±1.1 10.5±1.6
*IC50 value was defined the as the effective concentration of 
EGb 761 (µg/mL) preventing 50% of t-BHP oxidation. Data 
represents mean ± standard error of 5 analyses in triplicate.
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A majority of studies on the SCD population have 
reported deficits in concentration of GSH (Hebbel et al., 
1982; Wetterstroem, 1984; Hebbel, 1990; Hebbel, Leung, 
Mohandas, 1990; Aslan, Thornley-Brown, Freeman, 2000; 
Reid et al., 2006; Morris et al., 2008), while others have 
not found this pattern (Rice-Evans, Omorphos, Baysal, 
1986; Somjee et al., 2004; Manfredini et al., 2008; Nur et 
al., 2011). Moreover, the GSSG (oxidized glutathione)/
GSH index was significantly elevated in SCD patients, 
supporting an important role for oxidative damage in these 
cells (Morris et al., 2008; Rusanova, 2010).
Chaves (2007) found decreased basal levels of GSH 
in erythrocytes of HEMEPAR SCA patients. Besides, in 
our experiments, as well as in Hermann (2011), the basal 
content of GSH was the same in both groups. This result 
suggests a protective effect of recent drug therapy, as hy-
droxyurea, and improvement in healthcare of SCA patients 
against spontaneous oxidation in vivo.
In fact, effective preventive measures including 
newborn screening, education of patients and caregivers, 
nutrition support, protective vaccinations and prophylaxis 
using penicillin to prevent pneumococcal, contribute to a 
decrease in the morbimortality as well as to improve qual-
ity of life of these patients (Braga, 2007).
In erythrocytes exposed to t-BHP, lipid peroxidation 
and hemoglobin degradation represent the extremes in a 
spectrum of oxidative damage. The reduction of t-BHP by 
GSH peroxidase (with GSH oxidation) effectively spares 
membrane lipids from peroxidation. Also, consumption 
of t-BHP by reaction with hemoglobin results in the 
generation of initiators of lipid peroxidation (Trotta, Sul-
livan, Stern, 1983). In this study, the action of t-BHP as 
a pro-oxidizer was more accentuated in SS compared to 
AA erythrocytes, presenting approximately 40% greater 
membrane lipo-peroxidation, higher hemoglobin oxida-
tion, and near depletion of GSH levels.
When AAPH is added as an initiator, it decomposes 
at a physiological temperature (37 oC) in aqueous solutions 
to generate alkyl radicals (R•), which in the presence of 
oxygen, are converted to the corresponding peroxyl radi-
cals (ROO•). These peroxyl radicals induce the oxidation 
of polyunsaturated lipids (LH) in erythrocytes membranes, 
causing a chain reaction known as lipid peroxidation. As 
a result of lipid peroxidation, the membrane is quickly 
damaged and loses its integrity, leading to the release of 
hemoglobin (hemolysis) and intracellular K+ ions (Ba-
nerjee et al., 2008). In this study, AAPH displayed strong 
hemolytic effects in erythrocytes. As Tatum and Chow 
(1996) showed, SS erythrocytes were more resistant to 
AAPH-induced hemolysis compared to normal erythro-
cytes.
Compounds such as EGb 761 can scavenge peroxyl 
radicals and convert them to non-reactive species, result-
ing in the inhibition of hemolysis, lipid peroxidation and 
hemoglobin oxidation.
In fact, two well-documented mechanisms of action 
of EGb 761 are the scavenging of free radicals and the che-
lation of transition metals (Rong, Geng, Lau, 1996; Droy-
Lefaix, Packer, 1999; Lugasi, Horvahovich, Dworschak, 
1999; Smith,, Luo, 2004).
Kose and Dogan (1995) observed that the antioxi-
dant potential of EGb 761 on hydrogen peroxide-induced 
lipoperoxidation in healthy human erythrocyte membranes 
increased in a dose- and time- dependent manner, in vitro. 
He et al. (2008), observed the same pattern with the t-
BHP-induced formation of malonyldialdehyde in healthy 
human erythrocytes.
Furthermore, when the antioxidant effects of EGb 
761 were compared with those of water-soluble and lipid-
soluble antioxidants under the same in vitro system, EGb 
761 was more effective than ascorbic acid, glutathione and 
uric acid, and as effective as α-tocopherol and retinol ac-
etate (Kose, Dogan, 1995). Moreover, EGb 761 displayed 
a concentration- dependent inhibitory effect on MDA 
production in the erythrocytes of both Behcet’s patients 
(Kose et al., 1997) and G6-PD patients (Sarikcioglu, Oner, 
Tercan, 2004).
To our knowledge, it has not been reported that 
EGb 761 prevents oxidation in the erythrocytes of SCD 
patients. In our experiments, EGb 761 exhibited high anti-
oxidant activity in both AA and SS erythrocytes, inhibiting 
t-BHP-induced reactive oxygen species (ROS) production 
and preventing t-BHP-induced membrane peroxidation 
and AAPH-induced hemolysis. However, the oxidative 
process induced by t-BHP in human erythrocytes starts 
from the fast oxidation of GSH, oxidation of the oxyhemo-
globin, and then membrane lipid peroxidation. EGb 761 
could not prevent the first two steps of oxidative damage, 
as demonstrated by its failure to prevent hemoglobin and 
GSH oxidation in erythrocytes. Nevertheless, the ability 
of EGb 761 to effectively scavenge ROS species was able 
to prevent damage to red cells membranes.
Increased endogenous oxidative stress in SS eryth-
rocytes, as shown in Table I, was associated with severe 
damage induced by exogenous oxidants and is indicative 
of the need for increased antioxidant concentrations to re-
verse oxidative damage compared to control erythrocytes. 
CONCLUSION
It was observed in the present work that in vitro anti-
oxidant action of EGb 761 was dose-dependent, with IC50 
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at least two times greater in SCA erythrocytes than normal 
ones, preventing induced ROS production, membrane 
peroxidation and hemolysis. EGb 761 did not presented 
protective activity on GSH levels and hemoglobin oxida-
tion. Clinical trials are needed to investigate the action of 
EGb 761 in increase survival of SCA erythrocytes in vivo.
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